🚀 VC round data is live in beta, check it out!
Synmosa Biopharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Synmosa Biopharma and similar public comparables like Lexeo Therapeutics, Polaris Group, CytoDyn, Aclaris Therapeutics and more.
Synmosa Biopharma Overview
About Synmosa Biopharma
Synmosa Biopharma Corp is engaged in the research and development, manufacturing, marketing, and distribution of pharmaceutical products, medical devices, cosmetics, animal drugs, chemical food additives, and beverages. It is also involved in manufacturing and sales, and environmental drugs wholesale (retail), as well as the import and export of related businesses. The company provides prescription, OTC medicines, and healthcare products under its Synmosa trademark. The reporting segments of the company are; the Generic Drugs segment which derives key revenue, and the Active Pharmaceutical Ingredients segment.
Founded
1970
HQ
Employees
473
Website
Financials (FY)
EV
$498M
Synmosa Biopharma Financials
Synmosa Biopharma reported last fiscal year revenue of $196M and EBITDA of $38M.
In the same fiscal year, Synmosa Biopharma generated $85M in gross profit, $38M in EBITDA, and $26M in net income.
Synmosa Biopharma P&L
In the most recent fiscal year, Synmosa Biopharma reported revenue of $196M and EBITDA of $38M.
Synmosa Biopharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $196M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $85M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 43% | XXX | XXX | XXX |
| EBITDA | — | XXX | $38M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 19% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 13% | XXX | XXX | XXX |
| Net Profit | — | XXX | $26M | XXX | XXX | XXX |
| Net Margin | — | XXX | 13% | XXX | XXX | XXX |
| Net Debt | — | — | $18M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Synmosa Biopharma Stock Performance
Synmosa Biopharma has current market cap of $511M, and enterprise value of $498M.
Market Cap Evolution
Synmosa Biopharma's stock price is $1.01.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $498M | $511M | -0.2% | XXX | XXX | XXX | $0.05 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSynmosa Biopharma Valuation Multiples
Synmosa Biopharma trades at 2.5x EV/Revenue multiple, and 13.0x EV/EBITDA.
Synmosa Biopharma Financial Valuation Multiples
As of April 18, 2026, Synmosa Biopharma has market cap of $511M and EV of $498M.
Equity research analysts estimate Synmosa Biopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Synmosa Biopharma has a P/E ratio of 19.6x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $511M | XXX | $511M | XXX | XXX | XXX |
| EV (current) | $498M | XXX | $498M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 2.5x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 13.0x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 20.2x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 5.9x | XXX | XXX | XXX |
| P/E | — | XXX | 19.6x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 120.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Synmosa Biopharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Synmosa Biopharma Margins & Growth Rates
Synmosa Biopharma's revenue in the last fiscal year grew by 12%.
Synmosa Biopharma's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.1M for the same period.
Synmosa Biopharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 12% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 19% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 14% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 16% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 9% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 31% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Synmosa Biopharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Synmosa Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Lexeo Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Polaris Group | XXX | XXX | XXX | XXX | XXX | XXX |
| CytoDyn | XXX | XXX | XXX | XXX | XXX | XXX |
| Aclaris Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| MiMedx Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Synmosa Biopharma M&A Activity
Synmosa Biopharma acquired XXX companies to date.
Last acquisition by Synmosa Biopharma was on XXXXXXXX, XXXXX. Synmosa Biopharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Synmosa Biopharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSynmosa Biopharma Investment Activity
Synmosa Biopharma invested in XXX companies to date.
Synmosa Biopharma made its latest investment on XXXXXXXX, XXXXX. Synmosa Biopharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Synmosa Biopharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Synmosa Biopharma
| When was Synmosa Biopharma founded? | Synmosa Biopharma was founded in 1970. |
| Where is Synmosa Biopharma headquartered? | Synmosa Biopharma is headquartered in Taiwan. |
| How many employees does Synmosa Biopharma have? | As of today, Synmosa Biopharma has over 473 employees. |
| Is Synmosa Biopharma publicly listed? | Yes, Synmosa Biopharma is a public company listed on Taipei Exchange. |
| What is the stock symbol of Synmosa Biopharma? | Synmosa Biopharma trades under 4114 ticker. |
| When did Synmosa Biopharma go public? | Synmosa Biopharma went public in 2003. |
| Who are competitors of Synmosa Biopharma? | Synmosa Biopharma main competitors are Lexeo Therapeutics, Polaris Group, CytoDyn, Aclaris Therapeutics. |
| What is the current market cap of Synmosa Biopharma? | Synmosa Biopharma's current market cap is $511M. |
| What is the current revenue of Synmosa Biopharma? | Synmosa Biopharma's last fiscal year revenue is $196M. |
| What is the current EV/Revenue multiple of Synmosa Biopharma? | Current revenue multiple of Synmosa Biopharma is 2.5x. |
| Is Synmosa Biopharma profitable? | No, Synmosa Biopharma is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.